Armistice Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Armistice Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-88,000	Closed	-$9.05M	–	304
2023 Q2	$9.05M	Sell	88,000 -120,000	-58%	-$12.7M	0.13%	98
2023 Q1	$22.7M	Buy	+208,000	New	+$23M	0.33%	57
2018 Q2	–	Sell	-1,540,000	Closed	-$21.9M	–	95
2018 Q1	$21.9M	Buy	1,540,000 +540,000	+54%	+$7.98M	1.67%	26
2017 Q4	$14.6M	Buy	1,000,000 +200,000	+25%	+$2.81M	1.46%	24
2017 Q3	$10.1M	Sell	800,000 -20,000	-2%	-$254K	1.19%	33
2017 Q2	$9.73M	Sell	820,000 -30,000	-4%	-$373K	1.24%	32
2017 Q1	$12.6M	Buy	850,000 +200,000	+31%	+$3.24M	2.59%	16
2016 Q4	$10.5M	Buy	+650,000	New	+$11.8M	2.49%	13
2016 Q3	–	Sell	-400,000	Closed	-$6.59M	–	60
2016 Q2	$6.59M	Buy	+400,000	New	+$6.47M	2.51%	13

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

PCM

Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

HBK Investments Dallas, Texas $10.2B AUM 67.73% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.76B AUM 62.41% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Armistice Capital's HZNP Position: Q3 2023 in Review

Armistice Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2023, closing a stake of 88,000 shares — an estimated $9.05M sold.

Armistice Capital first reported a position in HZNP in Q2 2016 and held it in 9 quarters. The position peaked at $22.7M in Q1 2023. 485 funds tracked by Wall St. Rank hold HZNP as of Q3 2023.

Armistice Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2023 after selling out during the quarter.
Armistice Capital sold 88,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2023, an estimated $9.05M.
Armistice Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2016 and held it in 9 quarters.
Armistice Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $22.7M in Q1 2023.
485 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2023.

Based on Armistice Capital's 13F filing for Q3 2023, filed 14 Nov 2023.